Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 5/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183674 | 0.96 | GPBAR1 (0.76) | GPBAR1LMNAPKMTSHRUSP2 | |
| Sb-756050 SCHEMBL4174350 | 0.92 | GPBAR1 (1.00) | GPBAR1LMNAPKMTSHRUSP2 | |
| SCHEMBL6367892 | 0.90 | GPBAR1 (0.97) | GPBAR1LMNAPKMTSHRUSP2 | |
| SCHEMBL7209087 | 0.87 | GPBAR1 (0.91) | GPBAR1LMNAPKMTSHRUSP2 | |
| SCHEMBL4184681 | 0.87 | GPBAR1 (0.90) | GPBAR1LMNAPKMTSHRUSP2 | |
| SCHEMBL3830421 | 0.87 | GPBAR1 (0.90) | GPBAR1LMNAPKMTSHRUSP2 | |
| SCHEMBL7205052 | 0.86 | GPBAR1 (0.88) | GPBAR1LMNATSHRUSP2GLA | |
| SCHEMBL4181812 | 0.84 | GPBAR1 (0.80) | GPBAR1LMNAPKMTSHRUSP2 | |
| SCHEMBL13908368 | 0.84 | GPBAR1 (0.59) | GPBAR1LMNAPKMTSHRUSP2 | |
| SCHEMBL4177487 | 0.83 | GPBAR1 (0.82) | GPBAR1LMNAPKMTSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | claimed |
| EP-1976498-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-10-08 | — | — | EP | claimed |
| WO-2007127505-A2 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | WO | claimed |
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1976498-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007127505-A2 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127505-A2 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069302-A1 | CHEMICAL COMPOUNDS | TBXA2R, PDE4D, PDE4A | GPBAR1 81/4885LMNA 3674/4885PKM 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.